SG10201801219VA - Anti-HER2 Antibodies - Google Patents

Anti-HER2 Antibodies

Info

Publication number
SG10201801219VA
SG10201801219VA SG10201801219VA SG10201801219VA SG10201801219VA SG 10201801219V A SG10201801219V A SG 10201801219VA SG 10201801219V A SG10201801219V A SG 10201801219VA SG 10201801219V A SG10201801219V A SG 10201801219VA SG 10201801219V A SG10201801219V A SG 10201801219VA
Authority
SG
Singapore
Prior art keywords
her2 antibodies
antibodies
her2
bind
relates
Prior art date
Application number
SG10201801219VA
Inventor
Cheng-I Wang
Lionel Jianrong Low
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201801219VA priority Critical patent/SG10201801219VA/en
Priority to EP19754373.9A priority patent/EP3752536A4/en
Priority to CN201980025704.5A priority patent/CN112262156A/en
Priority to SG11202007735TA priority patent/SG11202007735TA/en
Priority to JP2020565255A priority patent/JP7460551B2/en
Priority to PCT/SG2019/050077 priority patent/WO2019160501A1/en
Priority to US16/969,119 priority patent/US11945877B2/en
Publication of SG10201801219VA publication Critical patent/SG10201801219VA/en
Priority to JP2023200834A priority patent/JP2024028777A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Abstract

Anti-HER2 Antibodies The present invention relates to antibodies that bind to the HER2 protein and the use thereof, [no suitable Figure]
SG10201801219VA 2018-02-13 2018-02-13 Anti-HER2 Antibodies SG10201801219VA (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SG10201801219VA SG10201801219VA (en) 2018-02-13 2018-02-13 Anti-HER2 Antibodies
EP19754373.9A EP3752536A4 (en) 2018-02-13 2019-02-12 Anti-her2 antibodies
CN201980025704.5A CN112262156A (en) 2018-02-13 2019-02-12 anti-HER 2 antibody
SG11202007735TA SG11202007735TA (en) 2018-02-13 2019-02-12 Anti-her2 antibodies
JP2020565255A JP7460551B2 (en) 2018-02-13 2019-02-12 Anti-HER2 antibody
PCT/SG2019/050077 WO2019160501A1 (en) 2018-02-13 2019-02-12 Anti-her2 antibodies
US16/969,119 US11945877B2 (en) 2018-02-13 2019-02-12 Anti-HER2 antibodies
JP2023200834A JP2024028777A (en) 2018-02-13 2023-11-28 Anti-HER2 antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201801219VA SG10201801219VA (en) 2018-02-13 2018-02-13 Anti-HER2 Antibodies

Publications (1)

Publication Number Publication Date
SG10201801219VA true SG10201801219VA (en) 2019-09-27

Family

ID=67621044

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201801219VA SG10201801219VA (en) 2018-02-13 2018-02-13 Anti-HER2 Antibodies
SG11202007735TA SG11202007735TA (en) 2018-02-13 2019-02-12 Anti-her2 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202007735TA SG11202007735TA (en) 2018-02-13 2019-02-12 Anti-her2 antibodies

Country Status (6)

Country Link
US (1) US11945877B2 (en)
EP (1) EP3752536A4 (en)
JP (2) JP7460551B2 (en)
CN (1) CN112262156A (en)
SG (2) SG10201801219VA (en)
WO (1) WO2019160501A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
MX2022000726A (en) 2019-07-19 2022-02-10 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof.
CA3184449A1 (en) * 2020-05-22 2021-11-25 GC Cell Corporation Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2023138666A1 (en) * 2022-01-19 2023-07-27 Utc Therapeutics (Shanghai) Co., Ltd. Circular rna and use thereof
WO2023150544A1 (en) * 2022-02-01 2023-08-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Simplified method of preparing cells for patient administration
WO2023196982A1 (en) * 2022-04-08 2023-10-12 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
CN114805584B (en) * 2022-06-30 2022-09-09 上海优替济生生物医药有限公司 Antigen binding proteins and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
NZ519191A (en) * 1996-10-18 2005-04-29 Univ Texas Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies
US20090304590A1 (en) 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2009055074A2 (en) 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
KR20110103980A (en) 2008-11-28 2011-09-21 노파르티스 아게 Pharmaceutical combinations comprising a pyrido[4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor
CN102167742B (en) 2010-02-25 2014-05-14 上海百迈博制药有限公司 Human monoclonal antibody against HER2, preparation method and purpose thereof
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
US9975960B2 (en) 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
CN106459916A (en) 2014-06-18 2017-02-22 乔治-施派尔-豪斯化学疗法研究所 Car-Expressing Nk-92 Cells As Cell Therapeutic Agents
EP3157560A4 (en) 2014-06-20 2018-02-21 Abgenomics International Inc. Her2 antibody-drug conjugates
KR101608301B1 (en) 2014-08-22 2016-04-12 앱클론(주) Antibodies Capable of Binding Specifically to HER2
WO2016135239A1 (en) * 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2
EP3271463A4 (en) 2015-03-18 2018-08-01 Baylor College of Medicine Her2/erbb2 chimeric antigen receptor
WO2017079694A2 (en) * 2015-11-04 2017-05-11 Priceman Saul J Chimeric antigen receptors targeting her2
CN106831987B (en) * 2015-12-04 2020-01-21 浙江大学 Anti-human HER2 antibody and coding gene and application thereof
EP3241847A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
EP3612202A2 (en) * 2017-04-21 2020-02-26 Baylor College of Medicine Oncolytic virotherapy and immunotherapy
CN107488636A (en) 2017-09-30 2017-12-19 山东兴瑞生物科技有限公司 A kind of immunocyte of anti-HER2 Chimeric antigen receptors modification for carrying molecular switch and its application

Also Published As

Publication number Publication date
JP7460551B2 (en) 2024-04-02
US11945877B2 (en) 2024-04-02
JP2021513368A (en) 2021-05-27
US20210139605A1 (en) 2021-05-13
CN112262156A (en) 2021-01-22
SG11202007735TA (en) 2020-09-29
WO2019160501A1 (en) 2019-08-22
JP2024028777A (en) 2024-03-05
EP3752536A4 (en) 2022-05-11
EP3752536A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
SG10201801219VA (en) Anti-HER2 Antibodies
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12018501882A1 (en) Binding proteins and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018008592A (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof.
MX2022010487A (en) Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof.
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
MX2022011659A (en) Antigen binding proteins that bind pd-l1.
MX2020010951A (en) Anti-hla-g antibodies and use thereof.
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.
MX2023005421A (en) Anti-vegf protein compositions and methods for producing the same.
EP3773716A4 (en) Monoclonal antibodies that bind to ssea4 and uses thereof
MX2019009498A (en) Fgf21 mimetic antibodies and uses thereof.
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
ZA202003320B (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
EP3904387A4 (en) Monoclonal antibodies that bind specifically to human trbv9
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2020010092A (en) C-terminal antibody variants.
EP3768722A4 (en) Novel anti-egfr antibody polypeptide
MX2021015473A (en) Novel antibodies specific for cthrc1 and use thereof.
MX2021007421A (en) Antibody that binds to vegf and il-1beta and methods of use.
EP3873514A4 (en) Monoclonal antibodies to eltd1 and uses thereof